CHMP recommends EU approval of Roche?s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer
- Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need
- First positive Phase III cancer immunotherapy study for people with metastatic triple-negative breast cancer